ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Company profile
Ticker
ACIU
Exchange
Website
CEO
Andrea Pfeifer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ACIU stock data
Latest filings (excl ownership)
F-3
Shelf registration (foreign)
14 Mar 24
6-K
Current report (foreign)
14 Mar 24
20-F
2023 FY
Annual report (foreign)
14 Mar 24
6-K
Current report (foreign)
22 Jan 24
6-K
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's diseases
3 Jan 24
6-K
Current report (foreign)
19 Dec 23
424B5
Prospectus supplement for primary offering
15 Dec 23
6-K
Current report (foreign)
15 Dec 23
6-K
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
1 Dec 23
6-K
Current report (foreign)
3 Nov 23
Latest ownership filings
SC 13G/A
AFFIRIS AG in Liqu
9 Feb 24
144
Notice of proposed sale of securities
28 Dec 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
19 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
144
Notice of proposed sale of securities
11 Dec 23
144
Notice of proposed sale of securities
6 Dec 23
144
Notice of proposed sale of securities
22 Aug 23
144
Notice of proposed sale of securities
21 Aug 23
144
Notice of proposed sale of securities
17 Aug 23
144
Notice of proposed sale of securities
9 Aug 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
50.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 6 |
Closed positions | 6 |
Increased positions | 8 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 45.62 bn |
Total shares | 50.12 mm |
Total puts | 20.90 k |
Total calls | 240.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
dievini Hopp BioTech holding GmbH & Co KG | 16.32 mm | $0.00 |
Biotechnology Value Fund L P | 7.43 mm | $0.00 |
BVF | 7.43 mm | $21.95 bn |
AFFiRiS | 6.72 mm | $20.98 mm |
LLY Lilly(Eli) & Co | 3.62 mm | $0.00 |
Avidity Partners Management | 2.90 mm | $8.58 bn |
MS Morgan Stanley | 1.76 mm | $5.20 bn |
Platinum Investment Management | 1.32 mm | $3.91 bn |
WFC Wells Fargo & Co. | 1.14 mm | $3.37 bn |
Renaissance Technologies | 417.98 k | $1.24 mm |
News
HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
15 Mar 24
AC Immune Received Decision To Grant European Patent EP3735411 "1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE"
8 Feb 24